EDCTP Alumni Network

Fostering excellence and collaboration in the next generation of researchers

Call EDCTP Clinical Research & Development Fellowship (R&D F)
Programme EDCTP2
Start Date 2020-02-01
End Date 2023-11-01
Project Code TMA2018IF-2484
Status Active


A systematic review of the efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria


Summarize the studies included in the review Compare the antimalarial treatment efficacy between HIV-infected and -uninfected Estimate PCR corrected risk for recrudescence in HIV-infected malaria patients Compare the risk of recurrence of parasitaemia in HIV-infected patients on different HIV treatments Gain skills in English course Gain skills in clinical trial design Gain skills in bio-statistical analysis Gain skills in protocol development and systematics reviews Acquire skills in other relevant training opportunities

Host Organisation

Institution Country
University of Oxford United Kingdom

Study Design

Context of project Work packages (WP) Objectives Description Deliverables from WP Communication plan Gantt chart Critical risks for implementation Budget justification Description of work to be conducted Define the Review question: What proportion of Pf malaria cases who are HIV positive in World fail treatment on oral ACTs? Search the following databases : PubMed, MEDLINE, EMBASE, Global Health, EBSCO CINAHL, Scopus, Web of Science Inclusion criteria: randomised control trial, quasi-randomised controlled trials, case-control studies, longitudinal studies- cohort studies Pharmacokinetic studies using drugs that are components of ACT Exclusion criteria: animal studies, case reports, case series, systematic reviews, literature reviews Condition or domain being studied : Falciparum malaria, PLHIV, treatment efficacy of ACTs

Current Organisation

Infectious Diseases Data Observatory, University of Oxford

Current Job Title

EDCTP-Fellow/ Visiting Researcher


2018 TMA2018IF-2484


Role Committee/board Start Date End Date
Reporter Institutional Ethic Committee of INSP 2021 2024


Institution Degree Year
Universite Joseph KI ZERBO, Burkina Faso PhD 2020-10-08
Universite Joseph KI ZERBO, Burkina Faso MSc 2011-07-14
Universite Joseph KI ZERBO, Burkina Faso Licence 2007-09-30

Areas Of Specialisation



African Journal of Pharmacy and Pharmacology
Evidence-Based Complementary and Alternative Medicine
Up to now, the control of malaria remains a challenge. The World Health Organization (WHO) recommends the use of artemisinin-based combination therapies (ACTs) for uncomplicated malaria treatment. Despite this guideline, many people in Burkina Faso use herbal medicine as primary treatment against malaria. The aim of this study was to assess the in vivo activity of Guiera senegalensis J. F. Gmel and Bauhinia rufescens Lam. leaves extracts against Plasmodium berghei ANKA. A four-day treatment of leaves decoction of each plant was administrated orally to 7 groups of six NMRI (Naval Medical Research Institute) mice infected with Plasmodium berghei ANKA strain. The control group received distilled water as treatment while the treated groups each received daily 100, 250, and 500 mg extract/kg body weight. Thin blood smears were performed on day five and the percentage of reduction of parasitaemia was determined compared to the control. The percentages of reduction of the parasitaemia at the doses of 100, 250, and 500 mg extract/kg body weight were, respectively, 57.5%, 35.9%, and 44.9% for Guiera senegalensis and 50.6%, 22.2%, and 25.7% for Bauhinia rufescens. Our findings on antiplasmodial activity of these two plants justify the traditional use by local populations against malaria. Thus, the isolation of the active compounds from these two plants is suggested for possible antimalarial candidate drugs.
DOI: 10.1155/2018/6859632
Part of ISSN: 1741-427X
Part of ISSN: 1741-4288
SIRIMA Sodiomon Bienvenu , Groupe de Recherche Action en Santé (GRAS), 06 BP 10248 Ouagadougou 06 Burkina Faso.
Academic Journal: African Journal of Pharmacy and Pharmacology

In the crude extracts of the bark and leaves of Sclerocarya birrea, have been characterized sterols,
triterpenes, saponosides, tannins, anthocyanosides, coumarins, reducing compounds, alkaloids and
carotenoids. Tests were carried out in vitro with extracts from each part of the plant to assess their
efficacy against strains of Plasmodium falciparum sensitive to chloroquine K1 and that resistant to
chloroquine 3D7. The crude alkaloidal extracts of the bark gave IC50 = 2.54 μg / ml with the strain 3D7
and an IC50 = 4.09 μg / ml with the strain K1. On the other hand, the extracts with CH2Cl2 showed an
IC50 = 36.59 and 37.78 μg / ml respectively with the 3D7 and K1 strains. Those with CH3OH gave IC50 all
greater than 50 μg/ml with both strains. The CH3OH / H2O extracts gave IC50 = 21.48 μg / ml with the K1
strain and greater than 50 μg / ml with 3D7. As for the H2O extracts, the IC50 were = 11.43 μg / ml with
the K1 strain and also greater than 50 μg / ml with the 3D7. The alkaloid extracts of leaf gave an IC50 =
9.68 μg / ml with 3D7 and = 3.56 μg / ml with strain K1. With CH2Cl2, and IC50 = 6.62 μg / ml was obtained
with 3D7 and 4.05 μg / ml with strain K1. The CH3OH extracts gave an IC50 = 21.12 μg / ml with the 3D7
strain and 21.06 μg / ml with the KI strain. The CH3OH / H2O extracts gave with strain 3D7 and IC50 of
more than 50 and 32.73 μg / ml with K1. The aqueous extracts gave IC50 greater than 50 μg / ml for 3D7
and 25.17 μg / ml with the K1 strain.

Not Informed: not informed
SCHOLARENA www.scholarena SAJ Pharmacy and Pharmacology

Send a Message